Somatostatin receptor-targeted organometallic iridium(iii) complexes as novel theranostic agents.
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(iii) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.